{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:13:08Z","timestamp":1778501588121,"version":"3.51.4"},"reference-count":40,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Background: Patient-centric endpoints increasingly influence clinical development, regulatory evaluation, and health technology assessment, yet the relevant methodological guidance remains distributed across separate domains. Estimands, digital health technologies, and real-world evidence are often addressed independently, making it difficult for sponsors to apply them within a single endpoint development strategy. This review synthesizes existing guidance and framework literature to organize these elements into a coherent lifecycle perspective for endpoint development. Methods: This semi-structured narrative review used a structured search of PubMed, Embase, and regulatory databases (FDA and EMA) for records published from January 2009 through December 2025. We synthesized authoritative guidance and peer-reviewed validation frameworks, including V3 and STaRT-RWE, and assessed landmark precedents (SV95C, ADAPTABLE, and RW-Response) selected a priori using pre-specified criteria for regulatory relevance, technical reporting, and first-of-kind pathway relevance. Results: The literature supports four recurring requirements for patient-centric endpoint development: early concept elicitation to establish meaningful aspects of health, explicit estimand specification to address intercurrent events, staged validation of digital measures under V3 principles, and formal validation of computable phenotypes for real-world evidence use. Across the reviewed sources, a recurring gap was the lack of an integrated framework linking these components across the evidence lifecycle. To address this, we organize existing guidance into an Integrated Lifecycle Roadmap that connects concept definition, measurement validation, causal inference, and real-world transportability. Conclusions: Patient-centric endpoints are most robust when they are developed as part of a continuous evidence lifecycle rather than as isolated study variables. The proposed roadmap does not introduce a new methodology, but it provides a practical structure for aligning existing regulatory and methodological frameworks to support scientifically rigorous and patient-relevant endpoint development.<\/jats:p>","DOI":"10.3390\/healthcare14101299","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:50:52Z","timestamp":1778496652000},"page":"1299","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Concept to Claim: An Integrated Lifecycle Roadmap (ILR) for Patient-Centric Endpoints in Clinical Trials and Real-World Evidence"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-2274","authenticated-orcid":false,"given":"Moustafa","family":"Kardjadj","sequence":"first","affiliation":[{"name":"CRO Division, dicentra, Toronto, ON M4W 3E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Almeida, D., Umuhire, D., Gonzalez-Quevedo, R., Ant\u00f3nio, A., Burgos, J.G., Verpillat, P., Bere, N., Sepodes, B., and Torre, C. (2024). Leveraging patient experience data to guide medicines development, regulation, and access decisions in the EU. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1408636"},{"key":"ref_2","first-page":"12","article-title":"A scoping review of frameworks evaluating digital health applications","volume":"8","author":"Maier","year":"2025","journal-title":"npj Digit. Med."},{"key":"ref_3","first-page":"e45","article-title":"Global perspectives on patient-centered outcomes: Advancing patient-centered cancer clinical trials","volume":"26","author":"Monge","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_4","unstructured":"ICH Expert Working Group (2019). ICH E9(R1) Addendum: Estimands and Sensitivity Analysis in Clinical Trials\u2014Addendum to the Guideline on Statistical Principles for Clinical Trials, International Council for Harmonisation."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41746-020-0260-4","article-title":"Verification, analytical validation and clinical validation (V3): The foundation of determining fit-for-purpose for biometric monitoring technologies (BioMeTs)","volume":"3","author":"Goldsack","year":"2020","journal-title":"npj Digit. Med."},{"key":"ref_6","unstructured":"U.S. Food and Drug Administration (2018). Framework for FDA\u2019s Real-World Evidence Program, FDA."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"m4856","DOI":"10.1136\/bmj.m4856","article-title":"STaRT-RWE: Structured template for planning and reporting on the implementation of real-world evidence studies","volume":"372","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2009). Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, FDA."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2021). CDER Patient-Focused Drug Development Clinical Outcome Assessment (COA) Compendium, FDA."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","article-title":"Recommendations for the use of patient-reported outcomes in medical product development: ISPOR ePRO Good Research Practices","volume":"12","author":"Coons","year":"2009","journal-title":"Value Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014Establishing and documenting the patient-centeredness of a PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"ref_12","first-page":"2231","article-title":"Principal Stratum strategy for handling intercurrent events in clinical trials","volume":"41","author":"Akacha","year":"2022","journal-title":"Stat. Med."},{"key":"ref_13","unstructured":"ICH (2021). ICH E9(R1) Training Materials: Module 2.3: Intercurrent Events and Estimands, International Council for Harmonisation."},{"key":"ref_14","unstructured":"European Medicines Agency (2023). Qualification Opinion on Stride Velocity 95th Centile (SV95C) as a Secondary\/Primary Endpoint in Ambulatory Duchenne Muscular Dystrophy Studies, EMA."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Baran, S.W., Bolin, S.E., Gaburro, S., van Gaalen, M.M., LaFollette, M.R., Liu, C.N., Maguire, S., Noldus, L.P.J.J., Bratcher-Petersen, N., and Berridge, B.R. (2025). Validation framework for in vivo digital measures. Front. Toxicol., 6.","DOI":"10.3389\/ftox.2024.1484895"},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration (2024). Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, FDA."},{"key":"ref_17","unstructured":"European Medicines Agency (2021). Guideline on Registry-Based Studies, EMA."},{"key":"ref_18","unstructured":"European Medicines Agency (2023). Guideline on the Use of Real-World Data in Registry-Based Studies, EMA."},{"key":"ref_19","unstructured":"European Medicines Agency (2024). DARWIN-EU: Second Report on Experience from Regulator-Led Studies and Progress of the Network (Feb 2023\u2013Feb 2024), EMA."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Janssens, R., Barbier, L., Muller, M., Cleemput, I., Stoeckert, I., Whichello, C., Levitan, B., Hammad, T.A., Girvalaki, C., and Ventura, J.-J. (2023). How can patient preferences be used in regulatory evaluation? Findings from IMI PREFER. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1192770"},{"key":"ref_21","first-page":"887","article-title":"Recommendations on health-related quality of life research to support labeling and promotional claims in the United States","volume":"9","author":"Revicki","year":"2000","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"VARC-3 Writing Committee, Genereux, P., Piazza, N., Alu, M.C., Nazif, T., Hahn, R.T., Pibarot, P., Bax, J.J., Leipsic, J.A., and Blanke, P. (2021). Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J. Am. Coll. Cardiol., 77, 2717\u20132746.","DOI":"10.1016\/j.jacc.2021.02.038"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate endpoints in clinical trials: Are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1186\/s13063-021-05644-4","article-title":"Estimands in published protocols of randomised trials: Urgent improvement needed","volume":"22","author":"Kahan","year":"2021","journal-title":"Trials"},{"key":"ref_25","first-page":"1105","article-title":"Estimands and role of statistics in clinical development for precision medicine in oncology","volume":"54","author":"Degtyarev","year":"2020","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_26","unstructured":"Digital Medicine Society (DiMe) (2026, February 16). The V3 Framework Resources and Community Guidance. Available online: https:\/\/datacc.dimesociety.org\/resources\/the-v3-framework\/."},{"key":"ref_27","first-page":"111","article-title":"A benchmarking resources for real-world evidence: The REPEAT initiative","volume":"113","author":"Wang","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yang, H., and Yu, B. (2021). Real-World Evidence in Drug Development and Evaluation, Chapman & Hall\/CRC.","DOI":"10.1201\/9780429398674"},{"key":"ref_29","unstructured":"Institute for Clinical and Economic Review (ICER) (2023). Considering Clinical, Real-World, and Unpublished Evidence, ICER."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","article-title":"Validation of a common data model for combined health data analytics","volume":"19","author":"Overhage","year":"2012","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available","volume":"183","author":"Robins","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_32","first-page":"596","article-title":"Rational Design and Registry-Based Recruitment of the ADAPTABLE Trial","volume":"5","author":"Roe","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_33","unstructured":"Friends of Cancer Research (2021). RW-Response Pilot (Real-World Tumor Response Pilot), FoCR."},{"key":"ref_34","first-page":"297","article-title":"Method agreement analysis: A review of correct methodology","volume":"184","author":"Watson","year":"2010","journal-title":"Vet. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","article-title":"The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments","volume":"19","author":"Mokkink","year":"2010","journal-title":"Qual. Life Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/cpt.3398","article-title":"Regulatory Pathways for Qualification and Acceptance of Digital Health Technology-Derived Clinical Trial Endpoints: Considerations for Sponsors","volume":"117","author":"Bakker","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/bcp.14388","article-title":"Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals","volume":"86","author":"Timpe","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e10034","DOI":"10.1002\/lrh2.10034","article-title":"Building the learning health system: Describing an organizational infrastructure to support continuous learning","volume":"1","author":"Kraft","year":"2017","journal-title":"Learn. Health Syst."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kijewski, S., McBride, C., Owens, E., Bernheim, E., and Vayena, E. (2026). Decentralized clinical trials: A comprehensive analysis of trends, technologies, and global challenges. PLoS Digit. Health, 5.","DOI":"10.1371\/journal.pdig.0001191"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101382","DOI":"10.1016\/j.lanepe.2025.101382","article-title":"Primary endpoint acceptance and its association with benefit ratings and market access in German health technology assessments: A retrospective cohort study","volume":"55","author":"Granold","year":"2025","journal-title":"Lancet Reg. Health Eur."}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/10\/1299\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:49:46Z","timestamp":1778500186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/10\/1299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["healthcare14101299"],"URL":"https:\/\/doi.org\/10.3390\/healthcare14101299","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}